Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Cue Biopharma's share price for the quarter that ended in Mar. 2024 was $1.89. Cue Biopharma's Shares Outstanding (EOP) for the quarter that ended in Mar. 2024 was 48.64 Mil. Therefore, Cue Biopharma's market cap for the quarter that ended in Mar. 2024 was $91.94 Mil.
Cue Biopharma's quarterly market cap
increased
from Sep. 2023 ($103.78 Mil) to Dec. 2023 ($124.65 Mil) but then
declined
from Dec. 2023 ($124.65 Mil) to Mar. 2024 ($91.94 Mil).
Cue Biopharma's annual market cap
declined
from Dec. 2021 ($364.21 Mil) to Dec. 2022 ($122.67 Mil) but then
increased
from Dec. 2022 ($122.67 Mil) to Dec. 2023 ($124.65 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Cue Biopharma's Enterprise Value for Today is $52.23 Mil.
Cue Biopharma Market Cap Historical Data
The historical data trend for Cue Biopharma's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Cue Biopharma's Market Cap
For the Biotechnology subindustry, Cue Biopharma's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cue Biopharma's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cue Biopharma's Market Cap distribution charts can be found below:
* The bar in red indicates where Cue Biopharma's Market Cap falls into.
Cue Biopharma Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Cue Biopharma's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cue Biopharma (NAS:CUE) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Cue Biopharma Market Cap Related Terms
Thank you for viewing the detailed overview of Cue Biopharma's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Cue Biopharma (Cue Biopharma) Business Description
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its drug candidate comprises CUE-101, a variant form of the cytokine Interleukin-2 and a T cell antigen to target and activate T cells specific to HPV-related cancers. The other products under pipeline are CUE-102, CUE-103, CUE-400, and CUE-401.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CUE has been successfully added to your 